Racemethionine

Racemethionine

SCHEMBL308235

CSCCC(N)C(=O)[O-].CSCCC(N)C(=O)[O-].CSCCC(N)C(=O)[O-].[Cr+3]

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNPEP Q9H4A4 1/20 0.42
ANPEP P15144 1/20 0.40
ENPEP Q07075 1/20 0.40
METAP2 P50579 1/20 0.37
METAP1 P53582 1/20 0.37
BHMT Q93088 5/20 0.36
BHMT2 Q9H2M3 1/20 0.36
NOS2 P35228 2/20 0.33
CYP3A4 P08684 2/20 0.33
TSHR P16473 2/20 0.33
NFKB1 P19838 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
CTSC P53634 1/20 0.33
FOLH1 Q04609 1/20 0.32
ARG1 P05089 1/20 0.32
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
PGGT1B P53609 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Racemethionine SCHEMBL308236 1.00 RNPEP (0.42) RNPEPANPEPENPEPMETAP2METAP1
Racemethionine SCHEMBL4852665 0.98 RNPEP (0.41) RNPEPANPEPENPEPMETAP2METAP1
Racemethionine SCHEMBL15111375 0.96 RNPEP (0.42) RNPEPANPEPENPEPMETAP2METAP1
Racemethionine SCHEMBL3898448 0.96 RNPEP (0.42) RNPEPANPEPENPEPMETAP2METAP1
Racemethionine SCHEMBL5150216 0.96 RNPEP (0.42) RNPEPANPEPENPEPMETAP2METAP1
Racemethionine SCHEMBL18886804 0.96 RNPEP (0.42) RNPEPANPEPENPEPMETAP2METAP1
Racemethionine SCHEMBL17473910 0.96 RNPEP (0.42) RNPEPANPEPENPEPMETAP2METAP1
Racemethionine SCHEMBL21221265 0.96 RNPEP (0.42) RNPEPANPEPENPEPMETAP2METAP1
Racemethionine SCHEMBL20553497 0.96
Racemethionine SCHEMBL3898443 0.96 RNPEP (0.42) RNPEPANPEPENPEPMETAP2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114065-A1 Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology BIONEXUS, LTD. 2008-05-15 US claimed
US-20040106591-A1 Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia BIONEXUS, LTD. 2004-06-03 US claimed
US-8093292-B2 Conjugated fatty acid or alcohol, thiol-containing compound and bioavailable form of trivalent chromium; preventing metabolic dysregulation of adipocytes resulting from HIV-1 infection or chronic inflammation BIONEXUS, LTD. (US) 2012-01-10 US disclosed
US-8017651-B2 Conjugated fatty acid or alcohol, thiol-containing compound and bioavailable form of trivalent chromium BIONEXUS, LTD. (US) 2011-09-13 US disclosed
US-20080114065-A1 Methods for the treatment of HIV-1 related fat maldistribution, fasting hyperlipidemia and modification of adipocyte physiology BIONEXUS, LTD. 2008-05-15 US disclosed
US-20040106591-A1 Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia BIONEXUS, LTD. 2004-06-03 US disclosed